Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Authors' conclusion
Randomised evidence suggests SGLT2 inhibitors enhance EQ-5D Index score, diabetes-specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
Study context
- Population
- Adults with T2D in RCTs and post hoc analyses reporting validated quality of life (QoL) or PRO outcomes; searched until 18 August 2025
- Participants
- 5,294 adults10 studies
- Comparison
- SGLT2i vs control
- SGLT2in = 2,807
- Controln = 2,487reference
- Outcome
- Validated QoL or PRO outcomes
Methodological detailsrandom-effects model, subgroup analyses by comparator (placebo, active), RoB-2 risk of bias
- Random-effects model
- Subgroup analyses by comparator (placebo, active)
- RoB-2 risk of bias
Pooled result
As reported in the abstract
- SGLT2i vs Placebo · EQ-5D Index score; improved with SGLT2i
- MD 0.04; P = 0.008
- SGLT2i vs Active comparators · DTR-QoL; improved with SGLT2i
- MD 6.99; P = 0.0006
- SGLT2i vs Active comparators · DTSQ; improved with SGLT2i
- MD 0.54; P = 0.006
- SGLT2i vs Placebo · IWQoL; improved with SGLT2i
- MD 1.44; P = 0.005
- SGLT2i vs Placebo · SHIELD WQ-9 overall QoL
- OR 2.11; P = 0.005
- SGLT2i vs Placebo · SHIELD WQ-9 emotional health
- OR 2.16; P = 0.006
- SGLT2i vs Placebo · SHIELD WQ-9 self-esteem
- OR 2.26; P = 0.006
- SGLT2i vs Placebo · SHIELD WQ-9 work performance
- OR 1.99; P = 0.04
Original publication
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 31 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →